Clinical trials: Psilocybin
Suicidal Ideation
Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PRE-EMPT will assemble a study group of 150 civilian and Veteran participants from three populations (low risk, intermediate risk, and high risk for self-harm).
- Trial name
- PRE-EMPT (NCT07484906)
- Testing
- fMRI Neurofeedback, Accelerated theta burst stimulation, Psilocybin assisted therapy
- Sponsor
- University of New Mexico
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain
This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain.
- Trial name
- NCT05506982
- Testing
- Psilocybin, Psychotherapy, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Major Depressive Disorder
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers
This randomized controlled clinical trial evaluates the effectiveness of psilocybin and psilocybin-assisted cognitive behavioral therapy (CBT) in the management of Major Depressive Disorder (MDD).
- Trial name
- NCT06746441
- Testing
- Psilocybin, Cognitive Behavioral Therapy (CBT)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Khyber Medical University Peshawar
Alcohol Use Disorder
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
This is a double-blind, randomized, placebo-controlled Phase 2 mechanistic clinical trial designed to evaluate the therapeutic neural mechanisms of psilocybin in patients with alcohol use disorder (AUD), and to determine whether…
- Trial name
- NCT06349083
- Testing
- Psilocybin, Supportive therapy sessions
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- NYU Langone Health
Alcohol Use Disorder
Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder
Note: The trial is only eligible for citizens of Denmark. The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients…
- Trial name
- NCT05416229
- Testing
- Psilocybin, Maltodextrin
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Cluster Headache
Psilocybin for the Treatment of Cluster Headache
The purpose of this study is to investigate the effects of an oral psilocybin pulse regimen in cluster headache. Subjects will be randomized to receive oral placebo, low dose psilocybin, or high dose psilocybin in three…
- Trial name
- NCT02981173
- Testing
- 0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Post Traumatic Stress Disorder, PTSD
Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD
A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).
- Trial name
- SUN004 (NCT06902974)
- Testing
- Psilocybin 25 mg
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Sunstone Medical
Major Depressive Disorder (MDD), Anxiety Disorders
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
This retrospective observational study examines the effects of psychedelic-assisted psychotherapy (PAP) with lysergic acid diethylamide (LSD) or psilocybin in patients with treatment-resistant depressive, anxiety, or addictive…
- Conditions
- Major Depressive Disorder (MDD), Anxiety Disorders, Substance Use Disorder (SUD), PTSD - Post Traumatic Stress Disorder
- Trial name
- NCT07164287
- Testing
- Lysergic Acid Diethylamide (LSD) or psilocybin
- Where
- Switzerland
- Volunteers
- 376 people
- Sponsor
- University Hospital, Geneva
Depression - Major Depressive Disorder
Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin
About one in three people with major depression respond poorly to standard antidepressant treatments. This kind of depression is called treatment-resistant depression, and it can lead to long-term disability, financial…
- Trial name
- NCT07164755
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- King's College London
Opioid Use Disorder
Psilocybin on Brain Mechanisms of Motivation in OUD
The goal of this study is to test addiction-related brain circuitry (motivation/reward and inhibition) as well as neurocognitive circuitry prior to and following low or high dose psilocybin (PEX010 from Filament).
- Trial name
- NCT06810310
- Testing
- Psilocybin (high dose), psilocybin (low dose)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Pennsylvania
Post-Treatment Lyme Disease, Chronic Lyme Disease
Effects of Psilocybin in Post-Treatment Lyme Disease
This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).
- Conditions
- Post-Treatment Lyme Disease, Chronic Lyme Disease, Lyme Disease, Chronic
- Trial name
- NCT05305105
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
This phase I trial tests the safety and side effects of a second episode of psilocybin-assisted group therapy and how well it works in treating anxiety and distress in patients with cancer that has spread from where it first…
- Trial name
- NCT06644170
- Testing
- Behavioral Intervention, Group Therapy, Psilocybin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Loneliness, Grief
The Effects of Psilocybin on Social Connectedness
The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional…
- Trial name
- NCT07693153
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Yale University
Obsessive-Compulsive Disorder
PsilOCD: A Pharmacological-Challenge Feasibility Study
The purpose of this study is to assess the impact of psilocybin on cognitive inflexibility and neural plasticity in a cohort of people with obsessive-compulsive disorder (OCD).
- Trial name
- NCT06258031
- Testing
- Psilocybin (COMP360)
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Imperial College London
Depressive Disorder, Major
A Study of Psilocybin for Major Depressive Disorder (MDD)
One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation…
- Trial name
- NCT03866174
- Testing
- Psilocybin, Niacin, Set and Setting (SaS) Protocol
- Where
- 11 sites in United States
- Volunteers
- 347 people
- Sponsor
- Usona Institute
End of Life
A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients
The purpose of the study is to understand the feasibility of a resilience focused community of practice program that includes psilocybin-assisted therapy for End-of-Life Distress.
- Trial name
- NCT05958758
- Testing
- Psilocybin-assisted therapy within a community of practice model (group administered)
- Volunteers
- 64 people
- Sponsor
- The Roots to Thrive Society for Psychedelic Therapy
Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
- Trial name
- P-TRD (NCT03775200)
- Testing
- Psilocybin
- Where
- 25 sites in United States, Canada and 8 more
- Volunteers
- 233 people
- Sponsor
- COMPASS Pathways
Psilocybin
The RECAP2 Study: Midazolam and Psilocybin
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in…
- Trial name
- NCT06692192
- Testing
- Psilocybin, Midazolam, Saline
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Anxiety and Depression
Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults
To investigate the efficacy of a 16 week treatment with PSIL428 patient reported anxiety levels in otherwise healthy individuals suffering from depression and or anxiety symptoms.
- Trial name
- NCT04989972
- Testing
- PSIL428, Oyster mushroom
- Where
- Jamaica
- Sponsor
- Wake Network, Inc.
Altered Waking States of Consciousness in Healthy Humans
Characterization of Altered Waking States of Consciousness in Healthy Humans
Altered waking states of consciousness and its underlying functional organization have gained increasing interest in recent years, i.e. in identifying the neural basis of consciousness.
- Trial name
- NCT03853577
- Testing
- TMS/EEG
- Where
- Switzerland
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Zurich